Back to search

Article

Short-Term Efficacy of Aflibercept 8 mg in Refractory Neovascular Age-Related Macular Degeneration: A Real-World Retrospective Case Series from Taiwan

2025-07-14

Abstract excerpt

<title>Abstract</title> <p> <bold>Purpose</bold> Aflibercept 8 mg is a newly developed option for neovascular age-related macular degeneration (nAMD) class. This study explores the short-term effectiveness of aflibercept 8 mg in patients with refractory nAMD. <bold>Method</bold> : <bold/> This retrospective case series analyzed patients with refractory nAMD who received aflibercept 8 mg at Taipei Veterans G...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
db940294-a2f9-511b-9f1c-5beb76ca9d24
DOI
10.21203/rs.3.rs-6993610/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Short-Term Efficacy of Aflibercept 8 mg in Refractory Neovascular Age-Related Macular Degeneration: A Real-World Retrospective Case Series from TaiwanDOI 10.21203/rs.3.rs-6993610/v1
Eighteen-Month Real-World Outcomes of Intravitreal Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A UK Single- Centre ExperienceSemantic proximity
Factors associated with achieving various visual acuity outcomes during loading doses of aflibercept 2mg for treatment naïve exudative age-related macular degeneration: PRECISE Study Report 7Semantic proximity
Sequential switch from first-line anti-VEGF therapy to faricimab and subsequent aflibercept 8mg in treatment-resistant neovascular AMDSemantic proximity
Clinical care and therapeutic practice of patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) and effectiveness of faricimab in treatment-naive patients in Germany - ZEUS research projectSemantic proximity
The Moorfields AMD Database Report 2 - Fellow Eye Involvement with Neovascular Age-related Macular DegenerationSemantic proximity
Dual pathway inhibition with faricimab for previously treated neovascular age-related macular degeneration and diabetic macular oedema: Guidance from a UK panel of retina specialistsSemantic proximity
Clinical Efficacy and Safety of Anti-vascular Biosimilars Compared to Reference Anti-vascular for neovascular age-related macular degeneration: A Systematic Review, Meta-Analysis and Meta-regression.Semantic proximity
Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.Semantic proximity
Result of Intravitreal Aflibercept Injection for Myopic Choroidal NeovascularizationSemantic proximity
Relationship between Aflibercept Efficacy and Genetic Variants of Genes Associated with Neovascular Age-Related Macular Degeneration: The BIOIMAGE Trial.Semantic proximity
Extended Duration Anti-VEGF Therapy for Chorioretinal Vascular Diseases: Successes, Failures and ChallengesSemantic proximity
Type 4 Macular Neovascularization in a Consecutive Age-Related Macular Degeneration Cohort: Prevalence and Multimodal Imaging FindingsSemantic proximity
Select a neighboring publication to make it the new centre.